semaglutide glp-1 injections Another Weight-Loss Trial Win for Weekly Drug Compound Semaglutide

Once you get to your station, you'll usually have one or two partners to move through the class with you

470 In this study, researchers randomized 529 patients with heart failure with a preserved ejection fraction and body mass index (weight in kilograms in the square of the height in meters) 30 to receive once-weekly injections of semaglutide (2.4 mg) or placebo for 52 weeks

Moderate-certainty evidence demonstrated that GLP-1 agonists probably decreased the risk of four-point major adverse cardiovascular events (composite outcome including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or need for hospitalization or coronary revascularization for unstable angina pectoris or heart failure) compared with placebo over a median 200 weeks of follow-up (risk ratio = 0.77

This effect matters during a cut